Systemic Relapse in a Young Adult Patient with Primary CNS Diffuse Large B-Cell Lymphoma

Table 1

Current CAR-T clinical trials in R/R PCNSL.

Sponsor	Study chair	Study design	Population	Conditions	Interventions	NCT
University College London	Claire Roddie	Phase I	Adults (>16 years)	(i) R/R PCNSL	Anti-CD19 CAR-T cells	NCT04443829
Massachusetts General Hospital	Matthew J. Frigault	Phase I	Adults (>18 years)	(i) R/R PCNSL	Tisagenlecleucel (anti-CD19 CAR-T cells)	NCT04134117
Dana-Farber Cancer Institute	Caron A. Jacobson	Phase I	Adults (>18 years)	(i) R/R CNSL; (ii) systemic lymphoma with concurrent CNSL	Axicabtagene ciloleucel (anti-CD19 CAR-T cells)	NCT04608487
Memorial Sloan Kettering Cancer Center	Jae Park	Phase I	Adults (>18 years)	(i) R/R CNSL; (ii) systemic lymphoma with concurrent CNSL	Anti-CD19 19 (T2) 28z1XX CAR-T cells	NCT04464200
Celgene	Claudia Schuster-bauer	Phase II	Adults (>18 years)	(i) R/R CNSL; (ii) systemic lymphoma with concurrent CNSL	Lisocabtagene maraleucel (anti-CAR-T cells)	NCT03484702
Zhejiang University	He Huang	Phase I	(i) Children (>3 years); (ii) Adults (18–75 years)	(i) ALL with CNS involvement; (ii) NHL with CNS involvement	Anti-CD19 CAR-T cells	NCT04532203
UNC Lineberger Comprehensive Cancer Center	Natalie Grover	Phase I	Adults (>18 years)	(i) R/R BCL; (ii) R/R PCNSL; (iii) R/R CLL/SLL	iC9-anti-CD19 CAR-T cells	NCT03696784
Shenzhen Genoimmune Medical Institute	Lung-Ji Chang	Phase I/II	(i) Children (>6 months); (ii) Adults (18–75 years)	(i) R/R BCL	4SCAR19 and 4scar20/22/70/PSMA/13/79b/GD2	NCT04429438

R/R: relapsed-refractory; PCNSL, primary CNS lymphoma; CAR-chimeric antigen receptor; NCT, national clinical trial identifier; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; BCL: B-cell lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; iC9: inducible caspase 9.